Quantinuum, the quantum computing subsidiary of Honeywell (NYSE: HON), is emerging as a dark horse in the quantum race. Unlike pure-play quantum companies burning cash, Quantinuum benefits from Honeywell’s industrial scale, a $300 million backlog, and a diversified revenue stream from trapped-ion quantum computers, quantum cybersecurity, and software. The company is targeting a spin-off or IPO within 12-18 months, which could unlock significant value.
Thesis
Quantinuum’s trapped-ion architecture is one of the most promising paths to fault-tolerant quantum computing. With a $300M backlog (up 50% YoY) and a path to positive EBITDA by 2027, the company offers a rare combination of technological leadership and financial discipline. The upcoming launch of the Helios quantum computer (expected 2026) and expansion into quantum cybersecurity (via Quantinuum’s Quantum Origin platform) provide clear catalysts.
12-Month Catalysts
- Helios Launch: The next-generation trapped-ion quantum computer with >50 logical qubits, targeting commercial applications in drug discovery and materials science.
- Spin-off/IPO: Honeywell has signaled a potential separation of Quantinuum, which could unlock a valuation premium.
- Backlog Conversion: The $300M backlog includes contracts with government agencies (e.g., DARPA, DOE) and enterprises (e.g., BMW, JPMorgan). Conversion to revenue is accelerating.
- Quantum Cybersecurity Growth: Quantinuum’s Quantum Origin platform is gaining traction in financial services and defense, with a 200% YoY increase in pilot programs.
Key Risks
- Spin-off Delay: If Honeywell delays the spin-off, the stock may not realize its full value in the near term.
- Technological Competition: Superconducting qubit approaches (Google, IBM) or photonic approaches (Xanadu) could leapfrog trapped-ion technology.
Valuation
At Honeywell’s current valuation (~$40B market cap), Quantinuum is effectively valued at ~$5-8B based on segment multiples. This implies a 2026E EV/Sales of ~8x, which is reasonable for a high-growth quantum business. A spin-off could drive a re-rating to 15x+ sales, implying a $10-15B valuation.
Balance Sheet
Honeywell has a strong balance sheet with $10B+ cash and low debt. Quantinuum is funded internally, with no near-term liquidity risk. The company is on track to reach EBITDA breakeven by 2027.
Disclaimer: This is not financial advice. Investing involves risk, including loss of principal. Do your own research.